Document is current

Article History

Received: 15 January 2023

Accepted: 12 February 2023

First Online: 15 April 2023

Declarations

:

: The authors declare the following conflicts of interest: Nizar J. Bahlis: Honoraria: Celgene, Janssen, AbbVie, Amgen, Sanofi, Takeda, Karyopharm Therapeutics, GlaxoSmithKline, Genentech/Roche; Consulting or Advisory Role: Janssen, Celgene, Amgen, Sanofi, Takeda, Pfizer, Karyopharm Therapeutics; Research Funding: Janssen (Inst), Celgene (Inst). Luciano J. Costa: Honoraria: Amgen, Celgene, Janssen, Karyopharm Therapeutics, Sanofi; Consulting or Advisory Role: AbbVie, Amgen, Celgene, Karyopharm Therapeutics; Speakers' Bureau: Amgen, Sanofi; Research Funding: Janssen, Amgen. Aurore Perrot: Honoraria: Amgen, Celgene, Janssen, Sanofi, Takeda, GlaxoSmithKline, AbbVie; Research Funding: Takeda (Inst); Travel, Accommodations, Expenses: Sanofi, Amgen, Janssen, Takeda, Celgene. Cyrille Touzeau: Honoraria: Abbvie, Celgene, Amgen, Takeda, Janssen, Sanofi, Novartis, GlaxoSmithKline; Consulting or Advisory Role: Novartis, Amgen, Celgene, Abbvie, Takeda, Janssen, GlaxoSmithKline; Research Funding: Abbvie. Mohamad Mohty: Honoraria: Celgene, Amgen, Bristol Myers Squibb, Janssen, Takeda, Pfizer, Astellas Pharma, Novartis, Jazz Pharmaceuticals; Consulting or Advisory Role: Jazz Pharmaceuticals, Sanofi, MaaT Pharma, Novartis, Xenikos, Adaptive Biotechnologies, GlaxoSmithKline; Speakers' Bureau: Janssen, Sanofi, Jazz Pharmaceuticals; Research Funding: Sanofi (Inst), Roche (Inst), Jazz Pharmaceuticals (Inst). Thierry Facon, Jean-Luc Harousseau, and Salomon Manier declare no conflicts of interest.